What is HC Wainwright’s Estimate for Immunic Q4 Earnings?

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at HC Wainwright issued their Q4 2024 earnings per share estimates for shares of Immunic in a note issued to investors on Monday, November 25th. HC Wainwright analyst M. Caufield expects that the company will post earnings per share of ($0.25) for the quarter. HC Wainwright has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.93) per share.

Other equities analysts have also issued reports about the company. StockNews.com lowered Immunic from a “hold” rating to a “sell” rating in a research report on Monday, November 11th. EF Hutton Acquisition Co. I upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 16th. Leerink Partners reiterated an “outperform” rating and issued a $5.00 price objective on shares of Immunic in a research report on Monday, September 9th. Leerink Partnrs upgraded Immunic to a “strong-buy” rating in a research report on Monday, September 9th. Finally, B. Riley initiated coverage on Immunic in a research report on Tuesday, August 27th. They issued a “buy” rating and a $6.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, five have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $11.80.

Immunic Price Performance

IMUX opened at $1.20 on Tuesday. The stock’s 50 day simple moving average is $1.37 and its 200 day simple moving average is $1.34. Immunic has a 1 year low of $0.97 and a 1 year high of $2.11. The firm has a market cap of $108.09 million, a price-to-earnings ratio of -0.98 and a beta of 1.88.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in IMUX. Vanguard Group Inc. raised its stake in Immunic by 100.7% during the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after buying an additional 1,703,047 shares during the last quarter. Janus Henderson Group PLC purchased a new position in Immunic during the first quarter valued at $9,266,000. Ikarian Capital LLC raised its stake in Immunic by 258.3% during the first quarter. Ikarian Capital LLC now owns 1,612,378 shares of the company’s stock valued at $2,128,000 after buying an additional 1,162,378 shares during the last quarter. Jane Street Group LLC raised its stake in Immunic by 121.4% during the third quarter. Jane Street Group LLC now owns 70,299 shares of the company’s stock valued at $116,000 after buying an additional 38,553 shares during the last quarter. Finally, State Street Corp raised its stake in Immunic by 7.5% during the third quarter. State Street Corp now owns 167,145 shares of the company’s stock valued at $276,000 after buying an additional 11,642 shares during the last quarter. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Insider Activity

In other news, Director Richard Alan Rudick bought 87,300 shares of the stock in a transaction dated Tuesday, November 12th. The stock was bought at an average price of $1.15 per share, for a total transaction of $100,395.00. Following the purchase, the director now directly owns 87,300 shares in the company, valued at $100,395. This trade represents a ? increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 3.00% of the stock is currently owned by company insiders.

Immunic Company Profile

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.